Poly Medicure Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 31 May 2026 | Healthcare Equipment & Supplies | Market Cap: ₹17.3K Cr
FY '27 consolidated revenue guidance: INR 2,300 to 2,400 crores, up from INR 1,875 crores in FY '26. - Stand-alone revenue guidance: INR 1,900 to 1,950 crores, with domestic business expected to grow over 20% and international business over 15%. - Export growth expected to recover with new product launches in the U.S. The company expects consolidated revenue of INR 2,300-2,400 crores in FY '27, up from INR 1,875 crores in FY '26, indicating ~25% growth. - Standalone revenue guidance is INR 1,900-1,950 crores, with domestic business growing over 20% and international business over 15%. - Standalone EBITDA margin is expected to be between 25%-27%, consistent with FY '26. - Consolidated EBITDA margin guidance is 23%-25%. - Growth drivers include ramp-up of high-technology products in cardiology, orthopedics, oncology, and renal care. - Focus on import substitution and innovation with over 399 patents underpin future profitability. - Export growth will benefit from easing logistics, increased presence in U.S.
From Poly Medicure Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,719
Market Cap
₹17.3K Cr
P/E Ratio
52.9
How does Poly Medicure Ltd rank in Healthcare Equipment & Supplies?
Compare Poly Medicure Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
Poly Medicure Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹535 Cr, net profit ₹65 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY '27 consolidated revenue guidance: INR 2,300 to 2,400 crores, up from INR 1,875 crores in FY '26.
- →Stand-alone revenue guidance: INR 1,900 to 1,950 crores, with domestic business expected to grow over 20% and international business over 15%.
- →Export growth expected to recover with new product launches in the U.S. and added distributors in Europe.
- →Strategic focus on higher-priced segments like orthopaedics, cardiology, neonatology, oncology, and renal care expected to improve margins and revenue mix.
- →Expect a sustained shift from infusion therapy revenue share decreasing to around 50%, with higher technology segments exceeding 50% revenue contribution.
- →Growth drivers include domestic import substitution, insurance penetration in India, direct market access in US, Europe, Brazil, and ongoing product innovation.
- →Management confident of 15-17% sustainable organic growth over next 3-5 years excluding acquisitions.
📈 Profitability & Margins
- →The company expects consolidated revenue of INR 2,300-2,400 crores in FY '27, up from INR 1,875 crores in FY '26, indicating ~25% growth.
- →Standalone revenue guidance is INR 1,900-1,950 crores, with domestic business growing over 20% and international business over 15%.
- →Standalone EBITDA margin is expected to be between 25%-27%, consistent with FY '26.
- →Consolidated EBITDA margin guidance is 23%-25%.
- →Growth drivers include ramp-up of high-technology products in cardiology, orthopedics, oncology, and renal care.
- →Focus on import substitution and innovation with over 399 patents underpin future profitability.
- →Export growth will benefit from easing logistics, increased presence in U.S. and European markets, and expanded distributor network.
- →Management believes worst disruptions are behind and sees sustainable organic growth in the mid-teens excluding acquisitions over the next 3-5 years.
🏗️ Capital Expenditure Plans
- →Poly Medicure Limited plans capex of INR 200 crores to INR 225 crores for FY '27, which is lower than last year's INR 296 crores.
- →Most capex projects from previous years are getting ready and operational.
- →Current focus is on automation to mitigate wage revisions and improve efficiencies.
- →The company is heavily investing in infrastructure and product development in areas like cardiology, orthopedics, oncology, and renal care.
- →New product launches include indigenously developed drug-eluting balloons and high-value products priced between INR 1 lakh to INR 10 lakh.
- →Strategic acquisitions (Citieffe, PendraCare, and a Brazil-based storage/distribution company) are in process with plans to integrate global supply chains and manufacturing.
- →Cost-saving projects and efforts to shift some manufacturing to India are underway to improve margins in recently acquired companies.
- →The infrastructure is being continuously strengthened to position the company for growth.
💰 Fundraising & Capital Structure
- →The company does not explicitly mention any current or upcoming fundraising through debt or equity in the provided transcripts.
- →Capex guidance for FY '27 is between INR 200 crores to INR 225 crores, which is lower than last year's INR 296 crores, indicating projects are nearing completion.
- →There is no mention of plans for additional QIPs (Qualified Institutional Placements) or debt issuances.
- →The focus appears to be on organic growth, capacity utilization, and operational efficiencies rather than on raising fresh capital.
- →However, the company is pushing for automation to mitigate wage increases, suggesting internal resource allocation rather than external fund raising.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Poly Medicure Ltd Q4 FY26 results?
FY '27 consolidated revenue guidance: INR 2,300 to 2,400 crores, up from INR 1,875 crores in FY '26. - Stand-alone revenue guidance: INR 1,900 to 1,950 crores, with domestic business expected to grow over 20% and international business over 15%. - Export growth expected to recover with new product launches in the U.S. The company expects consolidated revenue of INR 2,300-2,400 crores in FY '27, up from INR 1,875 crores in FY '26, indicating ~25% growth. - Standalone revenue guidance is INR 1,900-1,950 crores, with domestic business growing over 20% and international business over 15%. - Standalone EBITDA margin is expected to be between 25%-27%, consistent with FY '26. - Consolidated EBITDA margin guidance is 23%-25%. - Growth drivers include ramp-up of high-technology products in cardiology, orthopedics, oncology, and renal care. - Focus on import substitution and innovation with over 399 patents underpin future profitability. - Export growth will benefit from easing logistics, increased presence in U.S.
What is Poly Medicure Ltd share price analysis?
Poly Medicure Ltd currently shows a neutral. The stock trades at a P/E of 52.9 with a market cap of ₹17,317 Cr. Investors should review the full earnings analysis for detailed insights.
Is Poly Medicure Ltd planning capital expenditure?
Poly Medicure Limited plans capex of INR 200 crores to INR 225 crores for FY '27, which is lower than last year's INR 296 crores.
Keep Poly Medicure Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.